David R. Gandara

David R. Gandara, MD, is a Professor of Medicine and Senior Advisor to the Director at the UC Davis Comprehensive Cancer Center, where he has spent decades as one of the foremost clinical investigators in thoracic oncology. His research career has been defined by a systematic effort to identify predictive biomarkers that can guide the selection of systemic therapies for patients with non-small cell lung cancer (NSCLC), spanning chemotherapy, targeted agents, and, more recently, immunotherapy combinations. He has led or co-led numerous landmark phase II and phase III trials and served on international cooperative groups including SWOG and the International Association for the Study of Lung Cancer (IASLC). Gandara was among the early champions of combining platinum-based chemotherapy with immunotherapy in NSCLC, contributing to the scientific rationale that underpins regimens now considered standard of care. His work on blood-based tumor mutational burden (bTMB) from circulating tumor DNA sought to create a non-invasive surrogate biomarker for predicting benefit from checkpoint inhibitors, a concept that influenced the design of multiple industry-sponsored and academic trials. He has collaborated extensively with pharmaceutical partners and regulatory bodies to advance biomarker-driven trial design in lung cancer. Beyond bench-to-bedside translation, Gandara has made significant contributions to medical education and mentorship, training generations of oncologists at UC Davis and through national fellowship programs. He has served on the editorial boards of leading journals and as a member of guideline committees at ASCO and NCCN, shaping clinical practice recommendations for the management of advanced NSCLC. His career exemplifies the integration of basic science insights with pragmatic clinical investigation to improve outcomes for patients with thoracic malignancies.